Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update
Long Term Open Label Clinical Results Confirm That FMX101 Appears to be Safe and Well Tolerated; Continued Improvement of Treatment Effect Demonstrated at 52 Weeks Conference Call and Webcast on Wednesday, February 28, 2018 at 8:30am Eastern REHOVOT, Israel , Feb.
Toggle Summary Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28
REHOVOT, Israel , and BRIDGEWATER, N.J. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
Long Term Data on FMX-101 in Moderate-to-Severe Acne to be Presented at Winter Clinical Dermatology Conference ( January 12 th -17 th ) REHOVOT, Israel and BRIDGEWATER, N.J. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty
Toggle Summary Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals
REHOVOT, Israel and BRIDGEWATER, N.J. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, November 15, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , Nov. 15, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 15, 2017
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, August 9, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)   (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
Company validates clinical development pathway via FDA Type B Meeting REHOVOT, Israel , and BRIDGEWATER, New Jersey , Aug. 3, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary
Toggle Summary Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for August 9
REHOVOT, Israel and BRIDGEWATER, N.J. , July 26, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer
REHOVOT, Israel and BRIDGEWATER, New Jersey , June  29, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Pharmaceuticals to Present at the 2017 BIO International Convention
REHOVOT, Israel and BRIDGEWATER, New Jersey , June 15, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%
REHOVOT, Israel and BRIDGEWATER, New Jersey , June 12, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that
Toggle Summary Foamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey , June 1, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Reports First Quarter 2017 Financial Results and Provides Business Update
Conference Call and Webcast on Wednesday, May 10, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel , May 9, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (" Foamix Pharmaceuticals " or the "Company"), a clinical stage specialty pharmaceutical company focused on developing
Toggle Summary Foamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe Acne
Pooled Analyses of Phase 3 Data Show Additional Statistically Significant Effects on Primary and Secondary Efficacy Endpoints Commencement of 3 rd Phase 3 Trial Planned mid 2017; Submittal of NDA Planned in H2-2018 Conference Call and Live Webcast with Slides at 8:30am ET Tomorrow , May 2nd
Toggle Summary Foamix Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Health Care Conference
REHOVOT, Israel , and BRIDGEWATER, New Jersey , April 27, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology,
Toggle Summary Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, May 10
REHOVOT, Israel , and BRIDGEWATER, New Jersey , April 26, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (" Foamix Pharmaceuticals "), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs
Toggle Summary Foamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
Conference Call and Webcast Today at 8:30 a.m. EDT REHOVOT, Israel , and BRIDGEWATER, New Jersey , March 27, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), today announced the topline results of its two Phase 3 clinical trials investigating FMX101, Trial 04 and Trial 05, in
Toggle Summary Foamix Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey , March 8, 2017 /PRNewswire/ --  Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced
Toggle Summary Foamix Pharmaceuticals to Present at the ROTH Capital Partners 29th Annual Growth Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey , March 7, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced